Effect of Lupatadine Fumarate on Allergic Rhinitis
Study on the Effect and Mechanism of Lupatadine Fumarate in the Treatment of Allergic Rhinitis
This study is testing if Lupatadine Fumarate can help adults with allergic rhinitis feel better by reducing their symptoms like nasal congestion.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | The First Affiliated Hospital with Nanjing Medical University Academic / other |
| Locations | 2 sites (Nanjing, Jiangsu and 1 other locations) |
| Trial ID | NCT06709092 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness and underlying mechanisms of Lupatadine Fumarate in treating allergic rhinitis, a condition affecting a significant portion of the population in China. The research aims to explore how this medication, which has both antihistamine and platelet-activating factor antagonistic properties, alleviates symptoms such as nasal congestion. The study will include adult patients diagnosed with allergic rhinitis based on clinical history and specific sensitization tests. By examining the role of tight junction proteins and inflammatory pathways, the study seeks to provide insights into new therapeutic targets for this common allergy.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18-65 who have been diagnosed with allergic rhinitis and have positive dust mite sensitization tests.
Not a fit: Patients with recent use of certain medications, nasal diseases, or severe comorbid conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment options for patients suffering from allergic rhinitis.
How similar studies have performed: While the specific approach of using Lupatadine Fumarate is being explored in this study, similar antihistamine treatments have shown promise in managing allergic rhinitis in previous research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients (18-65 years). * Patients with allergic rhinitis were diagnosed based on clinical history and positive dust mite sensitization tests (skin prick test and/or specific IgE). Exclusion Criteria: * Received glucocorticoids, immunomodulatory, antihistamine drugs, and other medications that may affect the study results within the last 1 month. * Nasal diseases such as upper respiratory tract infections, chronic sinusitis with or without nasal polyps, and nasal sinus tumors. * History of nasal sinus surgery. * With other immune and allergic diseases. * Patients with a combination of severe cardiac, cerebrovascular or pulmonary - diseases, aspirin triad, primary ciliary dyskinesia, immune deficiency, and coagulation disorders. * Pregnant women. * Smokers.
Where this trial is running
Nanjing, Jiangsu and 1 other locations
- The First Affiliated Hospital with Nanjing Medical University — Nanjing, Jiangsu, China (Not_yet_recruiting)
- The First Affiliated Hospital with Nanjing Medical University — Nanjing, Jiangsu, China (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.